At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Impact of the Combined Treatment of Curcumin and Resveratrol Liposomed Polyphenols With G04CB02 on the Clinical Improvement of ALS Patients
In Brief
A Phase 2 clinical trial evaluating Liposomed polyphenols resveratrol and curcumin, Placebo for liposomed resveratrol and curcumin, and 3 other interventions for Amyotrophic Lateral Sclerosis. Completed, enrolled 90 participants across 1 site.
Detailed Summary
Amyotrophic lateral sclerosis (ALS) is a disease of an inflammatory nature, which causes progressive muscle weakness associated with cognitive and behavioural disorders. Pathogenically, it is characterised by loss of oxidative control, excitotoxicity due to excess glutamate and intestinal dysbiosis. In the absence of curative treatment, the aim of the study is to assess the impact at a clinical level of the combination of liposomed polyphenols to improve their effectiveness, with the drug G04CB02 which shows great anti-ALS properties by Molecular Topology methodology. A prospective, longitudinal, mixed, analytical, experimental and double-blind study is proposed, with a population sample of 60 patients distributed randomly in 30 patients in the intervention group who will receive treatment for 2 months, and 30 patients in the control group who will receive a placebo for the same period. The assessment will be at time 0, and at 2 months and 4 months after treatment, with functional, cognitive and behavioural tests, and of the state of inflammation and oxidation; and at time 0 and 2 months, of the intestinal microbiota.
Study Details
Timeline
Interventions
Combination of resveratrol (75mg) and curcumin (200mg) liposomed
Water with sucrose replacing the liposomed polyphenols
40% carbohydrates, 40% lipids and 20% proteins
G04CB02, in a single daily dose for 2 months
Placebo replacing G04CB02